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Background: In economic evaluation, cost per quality-adjusted life year (QALY) is generally used as an indicator for
cost-effectiveness. Although JPY 5 million to 6 million (USD 60, 000 to 75,000) per QALY is frequently referred to as
a threshold in Japan, do all QALYs have the same monetary value?
Methods: To examine the relationship between severity of health status and monetary value of a QALY, we
obtained willingness to pay (WTP) values for one additional QALY in eight patterns of health states. We randomly
sampled approximately 2,400 respondents from an online panel. To avoid misunderstanding, we randomly
allocated respondents to one of 16 questionnaires, with 250 responses expected for each pattern. After
respondents were asked whether they wanted to purchase the treatment, double-bounded dichotomous choice
method was used to obtain WTP values.
Results: The results clearly show that the WTP per QALY is higher for worse health states than for better health
states. The slope was about JPY −1 million per 0.1 utility score increase. The mean and median WTP values per
QALY for 16 health states were JPY 5 million, consistent with our previous survey. For respondents who wanted to
purchase the treatment, WTP values were significantly correlated with household income.
Conclusion: This survey shows that QALY based on the EQ-5D does not necessarily have the same monetary value.
The WTP per QALY should range from JPY 2 million (USD 20,000) to JPY 8 million (USD 80,000), corresponding to
the severity of health states.
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In economic evaluation, cost per quality-adjusted life
year (QALY) is generally used as an indicator of cost-
effectiveness [1,2]. Cost per QALY is calculated by div-
iding between-group differences in cost by differences
in obtained QALY, and is a type of incremental cost-
effectiveness ratio (ICER). The principal of QALY, “a
QALY is a QALY is a QALY” [3], implies that all QALYs
are of equal value. The question, however, is whether all
QALYs have the same monetary values. For example,
does QALY from cancer treatment have the same value
as QALY from flu prevention, from which many people
can recover without severe complications? Should the
gained QALYs of children suffering from genetic dis-
eases (for which they are not responsible) and those of* Correspondence: t.shiroiwa@gmail.com
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reproduction in any medium, provided the orsmokers affected by lung cancer be treated equally? Faced
by these issues, it is unlikely that many people accept the
concept “a QALY is a QALY is a QALY”. Of course, QALY
cannot fully reflect the preferences of people in terms of
their health states [4]. Hence, although QALY is a useful
indicator to improve the interpretation and comparability
of cost-effectiveness analysis, other important factors need
to be simultaneously considered when decision is made.
Cost-effectiveness of healthcare technologies is often
discussed by comparing ICER with a threshold, i.e.,
₤20,000-₤30,000 per QALY according to the National
Institute for Health and Care Excellence (NICE) guide-
lines [5]. Usually, this threshold is not explicitly strati-
fied by other factors, which are qualitatively considered
at the time of appraisal or decision making. However,
severity of health states and value of QALY are import-
ant issues. For example, in the UK, the introduction of
value-based pricing is being planned. A paper ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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there would be higher thresholds for diseases with a
higher ‘Burden of Illness.’ The most important factors
contributing to the measurement of ‘Burden of Illness’
would be the severity of the condition and the level of
unmet need” [6]. In the Netherlands, it has been sug-
gested that the threshold be adjusted from €10,000 to
€80,000 per QALY in proportion to severity.
Shah [7] reviewed empirical studies on severity of illness
and healthcare priority setting. The results mostly show
that greater resources are allocated to patients with se-
verer illnesses. Almost all studies measured public prefer-
ences by choice, ranking exercise, or the person trade-off;
however, it is unclear how severity is weighed in QALY-
based decision making. Nord et al. [8] suggested a method
to convert utility score to social value considering severity
weights obtained by the person trade-off. Unfortunately,
however, this method is not used widely for decision mak-
ing. Accordingly, we applied the willingness-to-pay (WTP)
method to obtain the monetary value of a QALY.
Our previous study [9] investigated the WTP values for
one additional QALY using double-bounded dichotomous
choice (DBDC), a contingent valuation method (CVM), in
six countries (Japan, Korea, Taiwan, UK, Australia, and the
US). The relationship between health states and WTP
per QALY was not evaluated. The EuroVAQ study mea-
sured WTP values per QALY in nine countries in
Europe (the Netherlands, UK, France, Spain, Sweden,
Norway, Denmark, Poland, and Hungary) [10-12], and
the results suggested that the WTP per QALY for worse
health state is higher than that for other states. More
empirical studies are needed to evaluate the relationship
between WTP and health states. This may contribute to
improved decision-making and reflecting the prefer-
ences of a greater number of people.
In Japan, the Ministry of Health, Labour and Welfare
(MHLW) has started a discussion on the introduction of
economic evaluation for decision-making from 2012. Until
now, economic evaluation has rarely been applied to Japa-
nese healthcare system. Although Japan has not decided
on how to use economic evaluation, its pros and cons and
applicability are now being considered. Although JPY 5
million to 6 million (USD 50, 000 to 60,000) per QALY is
frequently referred to as a threshold monetary value in
Japan, some people doubt the application of this single
threshold value. Therefore, we need to conduct empirical
research to determine the monetary value of a QALY.
Methods
Survey structure
We surveyed WTP per QALY for various treatment and
end-of-life scenarios. To determine whether severity of
health status influences the preferences of people for the
monetary value of a QALY, we obtained WTP values forone additional QALY for six health states (from severe to
mild). The six health states were defined using EQ-5D de-
scriptions: two mild states (State 1 = 11121 [Japanese EQ-
5D utility score of 0.769] and State 2 = 11212 [0.750]), two
moderate states (State 3 = 22122 [0.619], State 4 = 11323
[0.519]), and two severe states (State 5 = 23322 [0.386],
State 6 = 21333 [0.335]). As this study was designed to
compare Japan with other Asian countries, we used the
health states with similar EQ-5D scores relative to other
Asian countries (Korea and Thailand), excluding unrealis-
tic descriptions (e.g., a patient is confined to bed, but has
no problem with daily activities). In addition, WTP per
QALY for end-of-life situations was also examined. As two
patterns of end-of-life situations were considered, a total
of eight patterns were included in the survey.
Questionnaires
In the treatment scenario, respondents were asked to im-
agine they had an assumed health state as described based
on the EQ-5D (the six states mentioned above). If they did
not receive any treatment, they would live with the de-
scribed health state for XX months. After XX months,
they would recover full health. However, if they bought a
newly developed treatment and received it, they would im-
mediately recover full health. For each given assumed
health state, the WTP value was measured by the respon-
dents’ willingness to purchase the treatment.
We also specified the following conditions to each re-
spondent to clarify the assumed situation; (a) because the
treatment was not reimbursed by public health insurance,
the full amount had to be paid to receive it; (b) loss of in-
come due to the illness need not be considered (it is com-
pensated by social security, etc.); and (c) payment for the
treatment will influence the respondents’ household.
The number of months (XX), which was changed de-
pending on the health state, was calculated to equal
gained QALY (0.2 QALY and 0.4 QALY). For example,
in the case that the utility score of the health state was
0.40, the number of months was 12 x 0.2/(1–0.4) = 4
months (0.2 QALY) and 12 x 0.4/(1–0.4) = 8 months
(0.4 QALY). This also applied to end-of-life scenarios. In
the end, 16 questionnaires (8 patterns x 2 QALY types)
were constructed (Table 1). The QALY gain was deter-
mined by experts through discussions to reflect general
treatment and to set realistic duration in each scenario.
Given the feasibility of the study, only two levels of
gained QALY were applied.
“End-of-life scenario 1” reflected the assumption that re-
spondent life expectancy was one month in health state 6
[EQ5D description: 21333]. A newly developed treatment
could prolong life expectancy by seven months (0.2
QALY) or 14 months (0.4 QALY) in health state 6. “End-
of-life scenario 2” reflected a situation similar to that in
our previous survey [10]. Specific descriptions of health
Table 1 16 patterns of questionnaire
No Health state EQ5D description QALY Period (months)
1 Mild 11121 0.2 10
2 0.4 21
3 11212 0.2 10
4 0.4 20
5 Moderate 11323 0.2 5
6 0.4 10
7 22212 0.2 6
8 0.4 13
9 Severe 21333 0.2 4
10 0.4 7
11 23322 0.2 4
12 0.4 8
13 End-of-life 21333 0.2 7
14 0.4 14
15 Life threatening 0.2 2
16 0.4 5
Table 2 Bid value of double bound dichotomous choice
method
Assignment First bid-value* First answer Second bid-value*
1 20 (5%) No 10
Yes 40
2 40 (10%) No 20
Yes 80
3 80 (20%) No 40
Yes 160
4 160 (40%) No 80
Yes 320
5 320 (80%) No 160
Yes 480
6 480 (120%) No 320
Yes 600
*JPY 10,000 (percentage of GDP per capita).
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faced a life-threatening situation and life expectancy was
one month. Respondents were asked about their willing-
ness to purchase a treatment that could prolong life ex-
pectancy by two months (0.2 QALY) or four months (0.4
QALY) in perfect health.
Double-bounded dichotomous choice and bid value
In the present study, double-bound dichotomous choice
(DBDC) was used to obtain WTP for one additional
QALY. A bid value was shown and the respondents were
asked whether they would pay the bidding value for the
treatment. The CVM guidelines of the National Oceanic
and Atmospheric Administration (NOAA) in the US rec-
ommend the use of “Yes” or “No” vote [13]. In the DBDC
method, the question about willingness to purchase the
treatment is asked twice.
In our survey, respondents were asked whether they
wanted to purchase the treatment. Respondents who an-
swered “Yes” were randomly shown the following six bid
values (Table 2): JPY 0.2 million (USD 2,000, USD 1 = JPY
100, 5% of Japanese GDP per capita), JPY 0.5 million (USD
5,000, 10%), JPY 0.8 million (USD 8,000, 20%), JPY 1.6 mil-
lion (USD 16,000, 40%), JPY 3.2 million (USD 32,000, 80%)
and JPY 4.8 million (USD 48,000,120%). Respondents were
asked whether they would pay for the new treatment. De-
pending on the first answer, bid values were changed and
second-stage bid values were shown to the respondents. If
respondents answered “Yes” to the first question, a higher
bid value was shown in the second question and vice versa.
The range of second-stage bid values was JPY 0.1—6 mil-
lion (USD 1,000—60,000).Example of a questionnaire
A respondent was presented with the following DBDC
question.
“The following description is for assumed health status
A. Please imagine that you have this health status. If you do
not receive any treatment, you will recover perfect health
status B after you live for X months in health status A.
Now a new treatment has been developed. You can im-
mediately recover perfect health status B if you receive the
new treatment. However this treatment is not reimbursed
by public health insurance. You will have to pay the full
amount to receive it. Please respond to the questions after
considering the following situations: (a) payment for the
treatment will influence your household; (b) income loss
due to the illness need not be considered (it will be com-
pensated by other types of income, such as social security).”
Q1: Would you purchase the treatment by the smaller
amount ? [Yes/No]
Q2: Now please assume that the treatment cost is JPY
YYY. Would you purchase the treatment? [Yes/No]
Q3: Now please assume that the treatment cost is JPY
ZZZ. Would you purchase the treatment? [Yes/No]
Respondents
We randomly sampled approximately 2,400 respondents
from an online panel. The panel, which is the largest in
Japan, comprises 1.5 million people (INTAGE Inc.). In
Japan, the Internet penetration rate averages about 80%,
and almost all people under the age of 50 years have ac-
cess to the Internet. We recruited respondents aged 20
to 69 years, who were then stratified by age and sex.
This study was conducted in November 2011.To avoid
misunderstanding, we randomly allocated respondents
to one of 16 questionnaires, with 250 responses expected
for each pattern.
Table 3 Demographic characteristics of respondents
N Percentage
Age
20<= <30 444 19.5%
30<= <40 459 20.1%
40<= <50 449 19.7%













Household income (JPY 10,000)
<100 71 3.1%
100<= <200 110 4.8%
200<= <400 560 24.5%
400<= <600 633 27.7%
600<= <1000 633 27.7%
1000<= <1500 209 9.2%
1500<= <2000 46 2.0%
<2000 21 0.9%
Employment
Full-time worker 1019 44.6%
Part-time worker 339 14.9%
Self employment 178 7.8%
Homemaker 572 25.1%
Others (retirement…) 175 7.7%
Education
University or graduate 1277 55.9%
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Using the DBDC method, individual WTP values cannot
be obtained. From the responses, an acceptance curve,
which shows the relationship between probability an-
swering of a “Yes” response and bidding values, was gen-
erated. The mean WTP was obtained by calculating the
area under the acceptance curve (integrating acceptance
curve). The values were converted to WTP per QALY
by multiplying by 5 (0.2 QALY) or 2.5 (0.4 QALY).
The acceptance curve can be generated using a para-
metric or nonparametric method. We primarily used the
nonparametric Turnbull method [14] to obtain the con-
ditional WTP values (WTPc) of respondents who had a
WTP more than JPY 0. Letting the percentage of people
who answered “Yes” to the first question be pY, the mean
WTP can be calculated as “WTPc x pY”.
To determine influential factors for WTP, parametric
methods (logistic regression for the first question and
Weibull regression for the WTP part) were also applied to
all data (except for end-of-life scenario), including house-
hold income (continuous), education level (university or
graduate school = 1, reference: high school or less), em-
ployment status (full time = 1, reference: others), marital
status (married = 1, reference: not married), utility scores
of the presented health states (continuous), and QALY
(0.2 QALY or 0.4 QALY). Statistical software R 2.15.0 and
SAS 9.2 were used.
Results
A total of 2,283 respondents completed the questionnaire.
Demographic characteristics are shown in Table 3. Sam-
pling stratified by sex and age was successful. The average
household income of respondents was approximately JPY
6.2 million (USD 62,000, USD 1 = JPY 100), although that
of the average Japanese household, excluding elderly
households, was JPY 6.1 million (USD 61,000) in 2009
[15]. The proportion of the Japanese population in each
region in 2010 was 11.7% in Hokkaido/Tohoku, 33.1% in
Kanto, 16.9% in Chubu, 17.7% in Kansai, 5.9% in Chugoku,
3.1% in Shikoku, and 11.5% in Kyushu [16]. Respondent
demographics were similar to those of the Japanese gen-
eral population. According to the Organization for Eco-
nomic Co-operation and Development [17], data from
2009 indicated that 25% of the Japanese population
attained a tertiary education (type A, college, or graduate).
In our sample, 56% of respondents graduated from college
or graduate school. The education level was somewhat
higher in the study population.
The mean WTP values per QALY from each question-
naire are shown in Table 4, and the relationship between
WTP and utility score is presented in Figure 1. Figure 1
clearly shows that respondents were willing to pay more
money for worse health states (less utility scores), with the
regression line ranging from JPY 2 million (USD 20,000)to JPY 8 million (USD 80,000). The slope between WTP
values and utility score was about JPY −1 million (USD
1,000) per 0.1 utility score increase in the treatment situ-
ation. The mean and median WTP values per QALY for
16 health sates were JPY 5 million (USD 50,000), consist-
ent with our previous study.
Results of multivariable analysis are shown in Table 5.
Logistic analysis of the first question (respondents were
asked whether they wanted to purchase the treatment) re-
vealed that household income, education level, and marital
status significantly affected the respondents’ willingness to
Table 4 Estimate of WTP values
Q1
QALY N Yes No WTP per QALY*
Mild
state1: 11121 0.2 157 73 (46%) 84 (54%) 373
0.4 139 61 (44%) 78 (56%) 181
state2: 11212 0.2 146 72 (49%) 74 (51%) 412
0.4 139 73 (53%) 66 (47%) 217
Moderate
state3: 11323 0.2 144 84 (58%) 60 (42%) 615
0.4 134 84 (63%) 50 (37%) 298
state4: 22212 0.2 147 88 (60%) 59 (40%) 644
0.4 134 90 (67%) 44 (33%) 349
Severe
state5: 21333 0.2 149 93 (62%) 56 (38%) 824
0.4 139 90 (65%) 49 (35%) 573
state6: 23322 0.2 141 96 (68%) 45 (32%) 905
0.4 150 97 (65%) 53 (35%) 625
End-of-life
state7: 21333 0.2 139 43 (31%) 96 (69%) 534
0.4 142 67 (47%) 75 (53%) 524
state8: life
threatening
0.2 132 42 (32%) 90 (68%) 537
0.4 151 42 (28%) 106 (70%) 280
* JPY 10,000






























Figure 1 WTP for QALY and health states.
Table 5 Relation between WTP values and demographic
factors
Q1 WTP
Estimate p-value Estimate p-value
Household income
(per JPY 1 million)
0.0623 <0.001 0.0474 0.005
Education level 0.2161 0.041 0.0400 0.744
Pattern of employment 0.2000 0.063 0.0832 0.514
Marriage status 0.3348 0.002 −0.1922 0.153
Utility score of presented
health State
−1.7648 <0.001 −2.7035 <0.001
Scenario of QALY 0.0838 0.404 0.2381 0.044
Q1: Willing to pay more than JPY 1 for treatment.
WTP: Willing to pay the presented price in the questionnaire for treatment.
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ated with a higher probability of a “Yes” response to the
first question. For respondents who wanted to purchase
the treatment, WTP values were significantly correlated
with household income. The amount of gained QALY (0.2
QALY or 0.4 QALY) and utility scores of the presented
health states significantly affected the WTP values.
Discussion
In this study, we examined the WTP values for one add-
itional QALY and the relationship between WTP and
health states. In agreement with our previous empirical
study, the mean and median WTP values per QALY for
16 health state were JPY 5 million. Based on the results
of regression analysis (Figure. 1), the WTP per QALY
should range from JPY 2 million (USD 20,000) to JPY 8
million (USD 80,000), corresponding to the severity of
health states. It is possible that the choice of gained
QALY (0.2 or 0.4) influenced the WTP per QALY, and
that it is easier for respondents to accept the payment
for lower price treatment: these are limitations of our
survey.
The following three interpretations are possible to delib-
erately state that WTP per QALY is correlated with the se-
verity of health: (a) EQ-5D does not fully captureindividual health state preferences; (b) WTP inadequately
measures individual monetary value of a health state; and
(c) the monetary value of a QALY differs depending on
the severity of health states. From our empirical data, we
cannot exclude either one of the three interpretations. For
example, it is not deniable that scale of EQ-5D doesn’t
have the same interval with individual preference for
health states . However, we can conclude that at least in
this study, WTP per EQ-5D-based QALY does not appear
to be constant.
The principal “a QALY is a QALY is a QALY” is not
necessarily supported by our results, when it comes to
EQ-5D-based QALY. In the Netherlands, higher thresh-
olds (from €10,000 to €80,000) are allowed for interven-
tions aimed at increasingly severe illnesses [18]. Our
results suggest that these types of decision making may
reflect the preferences of people more appropriately. In
the Netherlands, the suggested slope of the threshold is
€ 7,000 (JPY 0.9million, € 1 = JPY130) per 0.1 point se-
verity increase. This value is similar to our slope of JPY 1
million (€8,000), although the unit of the denominator is
different. Of course, from the empirical data, we cannot
Shiroiwa et al. Cost Effectiveness and Resource Allocation 2013, 11:22 Page 6 of 7
http://www.resource-allocation.com/content/11/1/22say anything about WTP per QALY out of the range of
the utility score surveyed in this study.
If WTP is regarded as a factor for decision making based
on cost-effectiveness, it may be possible to change the
threshold based on the severity of health states to better
reflect public preferences. Of course, other factors that in-
fluence various social values should be simultaneously
considered. Some studies suggested introducing rules that
guide QALY-based decision making, including the Fair in-
nings rule [19], “Rule of Rescue” Egalitarian rule [8], and
proportional shortfall [20]. These rules are distinct from
the concept “a QALY is a QALY is a QALY.” However,
these rules, as well as severity-weighed QALY, conflict
with equity of QALY, which is applied to guidelines of eco-
nomic evaluations in some countries [21,22]. A priority
for severer patients may lead to discrimination of patients
with a milder health state.
In the “end-of-life” guidance, NICE is allowed to use the
utility scores of healthy people if the following conditions
are met [23]: (a) life expectancy is less than 24 months; (b)
life expectancy can be prolonged by 3 months; and (c) no
alternative treatment is available. However, in our survey,
the WTP in an end-of-life situation is not higher than that
for a [21333] health state in treatment. Given that this re-
sult is exploratory and limited, the relationship between
the end-of life situation and the WTP per QALY should
be more carefully evaluated.
The EuroVAQ study applied the so-called “chained
method,” in which respondents evaluate health states
using standard gamble (SG) or both time trade-off (TTO)
and WTP. According to the authors, the benefit of the
EuroVAQ method is that utility score can be obtained
from the same population in which WTPs are measured.
The EuroVAQ study also considered risk scenarios, which
measured WTP to avoid the possibility of the targeted
health state in addition to time scenarios similar to those
in our questionnaire. We think that risk scenario is im-
portant, and it will be considered in our future study.
Few studies have reported the measurement of WTP per
QALY in general settings. In some studies, the WTP per
QALY was calculated from the WTP for specific diseases.
The WTP value per QALY, as determined by Gyrd-Hansen
[24], was DKK 88,000. Using a method similar to that of
Gyrd-Hansen, Bobinac et al. [25] also measured WTP per
QALY and reported values ranging from €12,900 (based on
VAS valuations) to €24,500 (based on the Dutch EuroQoL
tariffs). Although the respondents were patients, King et al.
[26] reported WTP per QALY ranging from USD 12,500 to
USD 32,200. These results are lower than our estimated
WTP per QALY. The WTP per QALY from the EuroVAQ
study was different between the countries (Spain or
Denmark was the highest and the Netherlands, France, and
UK constituted the lowest group among 10 countries). The
total means ranged from €20,000 to € 35,000. Althoughmethods of existing studies differ, similar WTP values can
be obtained from other studies.
QALY is a useful tool for valuing health states to improve
the interpretation and comparability of cost-effectiveness
analysis. Yet, if we reject the unitarism of QALY, a Pandora's
box of conflicts – with regard to values and factors weighed
in decision making – may be opened. Of course various fac-
tors in addition to cost per QALY are implicitly and qualita-
tively considered at present [27]. Surely, decision making in
medicine should not be subject to people’s preferences
alone; however, it is important to empirically clarify people’s
preferences to improve the decision-making process and ob-
tain social consensus. Our survey alone is not sufficient to
this end, but it may contribute to this goal.
Conclusion
In this study, we examined WTP values for one additional
QALY and relation between WTP and health states. The
mean and median WTP values for QALY of the 16 scenar-
ios were around JPY 5 million. WTP per QALY for worse
health states are higher than those for better states. Al-
though the number of health states is not large in this sur-
vey, the slope is about JPY −1 million (USD 10,000) per
0.1 utility score increase. The results of the regression ana-
lysis suggested that the WTP per QALY should range
from JPY 2 million (USD 25,000) to JPY 8 million (USD
100,000). Therefore, it may be possible to change the
threshold based on the severity of health states to better
reflect public preferences.
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